What is the recommended dosing for the BPC-157 + TB-500 stack?

Research protocols typically use BPC-157 at 250–500 µg per injection (subcutaneous or intramuscular, near the site of injury) and TB-500 at 2–5 mg per injection. Dosing varies by study and intent; this is not medical guidance. Always consult literature for the protocol matching your research design.

How should BPC-157 and TB-500 be timed?

Common practice separates the two peptides by 4–12 hours or gives them on alternating days. The separation is intended to minimize pharmacokinetic interference and allow each peptide's mechanism to work independently. Some protocols inject one in the morning, the other in the evening.

Is the BPC-157 + TB-500 stack approved for human use?

No. Neither BPC-157 nor TB-500 is FDA-approved, and the combination has no human clinical trials or approval. The stack remains a research framing used in pre-clinical studies and is sold for research use only, not human consumption.

Research Peptides · Tissue Repair · Pre-Clinical

BPC-157 + TB-500 Stack Protocol: Research Guide to the Wolverine Peptide Combination

Q: What is the BPC-157 + TB-500 stack?

The BPC-157 + TB-500 stack (often called the 'Wolverine peptide' combination) pairs two research peptides with complementary mechanisms: BPC-157 promotes angiogenesis and fibroblast migration; TB-500 regulates actin polymerisation and cell motility. Pre-clinical studies suggest the combination targets tissue repair through non-overlapping pathways.

Q: Why stack BPC-157 and TB-500?

Animal research suggests complementary effects: BPC-157 acts primarily on fibroblast behaviour, blood vessel formation, and nitric oxide signaling; TB-500 enhances cell migration and actin-based motion. The rationale is that the two mechanisms may support each other in injury recovery models, though human trials remain absent.

Published Jun 4, 2026 · New-U Team · 8 min read

Quick answer: The BPC-157 + TB-500 stack (Wolverine peptide combination) pairs two research peptides with distinct mechanisms: BPC-157 targets angiogenesis and fibroblast migration; TB-500 regulates actin polymerisation and cell motility. Pre-clinical studies suggest complementary effects on tissue repair, but no human trials exist. Typical protocols separate the peptides by 4–12 hours and dose BPC-157 at 250–500 µg and TB-500 at 2–5 mg per injection. This is a research guide only; neither peptide is FDA-approved or intended for human use.

Why Stack BPC-157 and TB-500?

The rationale for combining BPC-157 and TB-500 comes from their non-overlapping mechanisms of action in pre-clinical research:

BPC-157 is thought to act primarily on blood vessel formation (angiogenesis), fibroblast behaviour, and the nitric oxide signaling system. Animal studies suggest it supports tissue remodeling by promoting cell migration and growth factor activity.
TB-500 (thymosin beta-4 fragment) is believed to regulate actin polymerisation—the process that drives cell motility and shape change. Pre-clinical evidence suggests it enhances cell migration and wound healing responses through a distinct molecular pathway.

Because the two peptides target different biological systems, the stacking logic is that they may work synergistically: BPC-157 primes the tissue environment (blood vessels, growth factors), while TB-500 enhances the cell migration machinery that executes repair. Neither peptide directly interferes with the other, and research protocols have explored both together in animal regeneration models.

Mechanism Comparison: BPC-157 vs. TB-500

Aspect	BPC-157	TB-500
Primary target	Angiogenesis, fibroblast migration	Actin polymerisation, cell motility
Key pathway	Nitric oxide signaling, growth factor modulation	Actin dynamics, cell shape change
Pre-clinical focus	GI healing, tendon repair, ulcer models	Muscle regeneration, wound healing, inflammation
Typical administration	Local injection near injury site	Systemic or local injection

Stacking Protocol: Timing and Dosing

Research protocols that use BPC-157 and TB-500 together typically follow these patterns:

Dosing

BPC-157: 250–500 µg per injection (subcutaneous or intramuscular, typically near the injury site)
TB-500: 2–5 mg per injection (systemic or local, depending on study design)

These ranges reflect published animal research; human dosing remains unknown because human trials do not exist. Dosing is highly dependent on the research model, target tissue, and experimental design.

Timing and Separation

Common practice separates the two peptides to minimize potential pharmacokinetic overlap:

Morning/Evening split: BPC-157 in the morning (e.g., 8 AM), TB-500 in the evening (e.g., 8 PM). This 12-hour separation allows each peptide's mechanism to work independently.
Alternating days: Some protocols inject one peptide on odd days and the other on even days, reducing frequency but extending treatment duration.
4-hour minimum: If using both on the same day, protocols typically space them at least 4 hours apart to allow absorption and avoid acute competition at the injection site.

Reconstitution and Storage

Reconstitute each peptide separately with bacteriostatic water (sterile water with 0.9% benzyl alcohol) to the desired concentration.
Store reconstituted solutions at 2–8°C (refrigerator) for short-term use (up to 2 weeks).
Store lyophilised (powder) peptides in a freezer (-20°C or below) in airtight containers away from moisture and light for long-term stability.
Do not refreeze once thawed.

Pre-Clinical Research Evidence

The BPC-157 + TB-500 combination has been explored in animal regeneration models, particularly in sports-injury and musculoskeletal contexts. Published studies include:

Tendon and ligament repair: Rat models of Achilles tendon injury and ACL damage show improved healing metrics (collagen deposition, vascularisation) when BPC-157 and TB-500 are combined.
Muscle injury recovery: Pre-clinical evidence suggests the stack reduces inflammation markers and accelerates myocyte regeneration in muscle-damage models.
Wound healing: Combined administration in skin-wound models shows faster re-epithelialisation and angiogenesis than either peptide alone.

However, all published evidence is from animal studies (rat, mouse, rabbit models). No human clinical trials have been conducted, and no human efficacy or safety data exist. The FDA has not approved either peptide for human use, and they remain research compounds only.

How the BPC-157 + TB-500 Stack Compares to Other Combinations

Research into peptide stacking has explored other pairings, each targeting different biological systems:

BPC-157 + GHK-Cu: Combines fibroblast support (BPC-157) with collagen remodeling (GHK-Cu); used in pre-clinical skin and wound models.
BPC-157 + IGF-1: Pairs angiogenesis (BPC-157) with growth signaling (IGF-1); explored in muscle and bone regeneration research.
TB-500 + MOTS-c: Combines cell motility (TB-500) with mitochondrial signaling (MOTS-c); emerging in metabolic and recovery research.

The BPC-157 + TB-500 stack remains the most commonly referenced "Wolverine" combination in sports-injury research forums and anecdotal literature, even though human evidence does not exist.

Safety and Tolerability in Pre-Clinical Research

Animal studies of BPC-157 and TB-500 individually report generally favourable tolerability profiles:

No acute toxicity has been observed at research doses in rodent and larger animal models.
Histological examination of injection sites shows no necrosis or chronic inflammation.
Systemic markers (liver, kidney, immune function) remain normal in long-term dosing studies.

However, animal tolerance does not predict human safety. The FDA has repeatedly emphasised that neither BPC-157 nor TB-500 has adequate human safety data, and the agency has not approved compounding of either peptide for human use. Any human use would be off-label and experimental.

Research Use Only

New-U catalogues both BPC-157 and TB-500 as lyophilised reference peptides for laboratory and research use only. They are not intended for human consumption, injection, or therapeutic application. Each batch includes a Certificate of Analysis certifying purity (>99% by HPLC) and is sold strictly for research purposes. Use is the sole responsibility of the end researcher.